Human Anti-HCV E2 Recombinant Antibody (AP33) (CAT#: TAB-020CT)

Figure 1 Analysis of E1E2 of diverse HCV genotypes.

A series of threefold dilutions of lysates of HEK 293T cells cotransfected with the MLV packaging/transfer vector and a plasmid expressing E1E2 of different HCV genotypes were analyzed for the presence of E2 by GNA capture ELISA using MAb AP33 (•) or ALP98 (○) (at 1 μg/ml) or the polyclonal antiserum R646 (▴) (1:10,000 dilution) as described in Materials and Methods

Owsianka, A., Tarr, A. W., Juttla, V. S., Lavillette, D., Bartosch, B., Cosset, F. L., ... & Patel, A. H. (2005). Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. Journal of virology, 79(17), 11095-11104.

Figure 2 Analysis of E1E2 of diverse HCV genotypes.

Radiolabeled proteins in the lysate of HEK 293T cells cotransfected with different plasmids as described in A above were immunoprecipitated using a mixture of anti-E2 MAbs AP33 and ALP98. The immune complexes were analyzed by SDS-10% PAGE under reducing conditions. Positions of protein size markers are shown (in kDa).

Owsianka, A., Tarr, A. W., Juttla, V. S., Lavillette, D., Bartosch, B., Cosset, F. L., ... & Patel, A. H. (2005). Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. Journal of virology, 79(17), 11095-11104.

Figure 3 Neutralization by MAb AP33 of HCVpp derived from diverse genotypes.

HCVpp were preincubated for 1 h at 37°C with different concentrations of purified MAb AP33 prior to infection of Huh-7 cells. The neutralizing activity of the antibody is expressed as percentage of inhibition of the infectious titers.

Owsianka, A., Tarr, A. W., Juttla, V. S., Lavillette, D., Bartosch, B., Cosset, F. L., ... & Patel, A. H. (2005). Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. Journal of virology, 79(17), 11095-11104.

Figure 4 Inhibition of HCV-LPs binding to cells by anti-E1 and anti-E2 antibodies.

SYTO-labeled HCV-LPs were preincubated with 20 to 100 μg of anti-E2 (AP33 and ALP98), anti-E1 (A4), or isotype control IgG/ml for 2 h at 4°C. The HCV-LP-antibody mixtures were then incubated with Molt-4 cells for 1 h. The cell-bound HCV-LPs were analyzed as described in the text. Flow cytometry histogram of HCV-LPs binding in the presence (20 μg/ml) (open graph) or absence (black graph) of antibodies. The background binding is shown as the gray graph.

Triyatni, M., Saunier, B., Maruvada, P., Davis, A. R., Ulianich, L., Heller, T., ... & Liang, T. J. (2002). Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. Journal of virology, 76(18), 9335-9344.